GlobeNewswire by notified

Teledyne DALSA announces its new line of high-performance X-ray detectors at RSNA 2022

Share

New Axios IGZO-based X-ray detectors deliver an unrivaled balance of performance and value

WATERLOO, Ontario, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Teledyne DALSA is pleased to announce its presence at the RSNA 2022 Technical Exhibition with a new offering of X-Ray detectors based on Indium Gallium Zinc Oxide (IGZO) in addition to their premium line of CMOS-based detectors. The show takes place November 27 - December 1, Chicago, IL. Teledyne will exhibit its full line of detectors in booth #3709.

Teledyne will introduce its breakthrough line of X-ray detectors that narrows the gap between amorphous silicon and CMOS-based detectors at RSNA 2022. The new Axios flat panel detector series, designed and manufactured entirely by Teledyne, are based on an innovative IGZO technology, proprietary new image chain and use the highest performance components. The Axios product line is engineered to deliver an unprecedented balance of performance and value, while addressing the needs of the most demanding real-time applications for diagnostic and interventional imaging like orthopedics, vascular cardiology and surgery. The high image quality performance of the Axios detectors will enable better diagnosis of medical anomalies and better procedure outcomes, resulting in reduced treatment costs.

“Axios detectors exceed industry benchmarks in current TFT detector technologies by providing artifact-free images at higher speeds and higher DQE at low dose operation with lower lag and an increased signal-to-noise ratio,” said Mila Heeman, Marketing Manager for Teledyne DALSA’s X-Ray Solutions business unit. “The Axios detectors produce high performance 2D and 3D imaging at a considerably lower cost than the premium CMOS technology detectors. We are happy to offer more affordable, high-performance X-ray imaging bearing the Teledyne stamp of excellence in product quality and customer support.”

On display will be also the Teledyne’s Xineos CMOS X-Ray detector series – a superior performance family of detectors that deliver unsurpassed low dose and lag-free image quality, combined with easy integration and long reliable lifetime. These detectors provide the best digital imaging solution for challenging surgical situations — where all other technologies stop working, Teledyne’s CMOS goes the extra mile. Teledyne has a full portfolio of CMOS detectors in a wide range of detector sizes and resolutions for demanding x-ray imaging applications such as surgery, 2D and 3D mammography, extra oral dental, CBCT and others.

About Teledyne DALSA’s Healthcare Products and Services
Teledyne DALSA provides state-of-the-art image sensing, capture and processing solutions to medical, dental and scientific equipment manufacturers. Building on more than 30 years of proven capability and innovation, our team of imaging specialists delivers leading-edge product design. Our manufacturing processes are tailored to comply with the stringent quality, reliability, and traceability requirements of the medical and scientific X-ray community. For more information, visit http://teledynedalsa.com/imaging/markets/medical/

Media Contact:
Geralyn Miller
geralyn.miller@teledyne.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe50b5a8-c2fb-4a26-9188-a39f0ca35b74

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Udstedelse af RSU program18.5.2024 11:34:18 CEST | pressemeddelelse

I overensstemmelse med bemyndigelsen fra generalforsamlingen den 18. april 2024 har bestyrelsen i dag indført et incitamentsprogram for selskabets bestyrelse. Incitamentetprogrammet er designet og struktureret omkring konceptet med at fastholde medlemmer af bestyrelsen samtidig med at der skabes incitament til en positiv aktiekursudvikling og virksomhedens resultater til gavn for selskabets aktionærer. Incitamentsprogrammet inkluderer Restricted Share Units ("RSU'er"), som giver ret til at deltagerne tildeles et antal aktier svarende til antallet af optjente RSU'er mod betaling af udnyttelseskursen. Programmet er underlagt en række betingelser som deltagerne skal overholde og som betyder at selskabet maksimalt vil skulle udstede 2.025 aktier til kurs 1.056 DKK forudsat at alle betingelser overholdes samt at den enkelte vælger at udnytte sine RSUér. Den beregnede værdi af programmet til den samlede bestyrelse ved brug af Black & Scholes er opgjort til DKK 350.146. Vestingkursen er bereg

Constellation Brands Announces Updated Time of Presentation at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202418.5.2024 01:05:50 CEST | Press release

VICTOR, N.Y., May 17, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announces an updated time that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a previously announced fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 4:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News&Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non- GAAP financial mea

DBV Technologies Announces Plan to Implement ADS Ratio Change17.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about June 3rd, 2024 (the “Effective Date”). For the Company’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-two reverse ADS split and is intended to enable the Company to regain compliance with

Oculis updates share capital for its existing at-the-market offering program17.5.2024 22:30:00 CEST | Press release

ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 1,000,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 46,443,700, of which 41.7 million shares are outstanding. The New Shares were issued following the Company and Leerink Partners LLC (”Leerink Partners”) entering into a sales agreement (the "Sales Agreement") with respect to an at-the-market offering program on May 8, 2024 under which the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The Company is

Metasphere Labs Unveils Decentralized Identity System at Consensus 2024 and Announces Carbon Aware Routing Protocol17.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce its participation in Consensus 2024 alongside Bot Ventures Inc. (“Bot Ventures”), where they will unveil an early demonstration of their innovative decentralized identity and domain name system. This platform utilizes Bitcoin blockchain technology to enhance online security and trust through decentralized digital identity solutions. Parties interested in seeing a demonstration of the prototype can book a meeting at Metasphere's private suite by contacting Natasha Ingram at info@metasphere.earth. New Carbon Aware Routing Protocol Initiative In addition to the demonstration, the Company is excited to announce a pioneering initiative to develop a carbon aware routing protocol for computer networks and the Internet. This protocol will enable Internet Service Providers (ISPs) a

HiddenA line styled icon from Orion Icon Library.Eye